Skip to main content
Equibles
LUNG logo

LUNG · Pulmonx Corp · Webcasts, Transcripts & Audio

Track LUNG — free

Use LUNG with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LUNG.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.91 +0.00 (+0.00%) At close · Oct 1
Rebalance outlook locked
Market Cap
$82.03M
Shares
42.95M
Volume · Oct 1 166.79K Avg daily vol (3M) 475.76K

Pulmonx Corp Webcasts

Earnings calls, investor updates, investor days and conferences for Pulmonx Corp (LUNG), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲1.8% $13.50M −$14.17M '22 Q3 22-11-03 ▲12.5% $15.43M −$14.28M '22 Q4 23-02-22 ▲34.8% $14.54M −$15.86M '23 Q1 23-05-02 ▲23.3% $17.19M −$16.20M '23 Q2 23-08-02 ▲30.9% $17.67M −$14.90M '23 Q3 23-10-10 ▲25% $19.28M −$13.89M '23 Q4 24-02-21 ▲29.7% $18.85M −$13.75M '24 Q1 24-05-01 ▲20.9% $20.78M −$15.33M '24 Q2 24-07-31 ▲15.4% $20.39M −$14.14M '24 Q3 24-10-30 ▲23.3% $23.77M −$13.18M '24 Q4 25-02-19 ▲19.5% $22.54M −$14.45M '25 Q1 25-04-30 ▲14.8% $23.86M −$15.17M '25 Q2 25-07-30 ▲5.5% $21.50M −$13.96M '25 Q3 25-11-12 ▼4.9% $22.60M −$10.43M '25 Q4 26-03-04 ▼8.7% $20.59M −$13.65M '26 Q1 26-04-29 LATEST ▼4.6% $22.76M −$10.08M '26 Q2 26-07-29
Conference
Investor event
2026-08-11
Pulmonx Corp (LUNG) August 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-07-29
Pulmonx Corp (LUNG) Q2 2026 Earnings Call Transcript
Positive tone China registration and resumption AerSeal / CONVERT-2 clinical program Operating leverage and cost reduction
Revenue
$22.76M
▼ 4.6% YoY
Diluted EPS
$-0.24
Gross margin
78.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-04-29
Pulmonx Corp (LUNG) Q1 2026 Earnings Call Transcript
Positive tone China distributor / registration Guidance and outlook Clinical pipeline / market expansion
Revenue
$20.59M
▼ 8.7% YoY
Diluted EPS
$-0.33
Gross margin
77.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-04
Pulmonx Corp (LUNG) Q4 2025 Earnings Call Transcript
Balanced tone U.S. Sales Reacceleration Clinical Initiatives and Market Expansion Cost Realignment and Profitability
Revenue
$22.60M*
▼ 4.9% YoY
Gross margin
77.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Pulmonx Corp (LUNG) Q3 2025 Earnings Call Transcript
Cautious tone Slowing U.S. growth and commercial execution Path to profitability and strategic refocus Q3 2025 financial results
Revenue
$21.50M
▲ 5.5% YoY
Diluted EPS
$-0.34
Gross margin
74.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Pulmonx Corp (LUNG) Q2 2025 Earnings Call Transcript
Cautious tone Capacity and Lung Cancer Screening Tailwinds International / OUS Growth LungTrax Detect AI Screening Tool
Revenue
$23.86M
▲ 14.8% YoY
Diluted EPS
$-0.38
Gross margin
72.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-30
Pulmonx Corp (LUNG) Q1 2025 Earnings Call Transcript
Positive tone Acquired test and treat commercial strategy Physician and patient education Revenue performance and full-year guidance
Revenue
$22.54M
▲ 19.5% YoY
Diluted EPS
$-0.36
Gross margin
72.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-19
Pulmonx Corp (LUNG) Q4 2024 Earnings Call Transcript
Confident tone Acquire, Test, Treat Strategy International Expansion Revenue Growth and Guidance
Revenue
$23.77M*
▲ 23.3% YoY
Gross margin
74.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Pulmonx Corp (LUNG) Q3 2024 Earnings Call Transcript
Positive tone Zephyr Valve Commercial Expansion Revenue Growth and Guidance Physician and Patient Awareness
Revenue
$20.39M
▲ 15.4% YoY
Diluted EPS
$-0.36
Gross margin
73.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-31
Pulmonx Corp (LUNG) Q2 2024 Earnings Call Transcript
Confident tone International / European Seasonality US Commercial Growth & Account Expansion Full-Year 2024 Revenue Guidance
Revenue
$20.78M
▲ 20.9% YoY
Diluted EPS
$-0.39
Gross margin
73.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-01
Pulmonx Corp (LUNG) Q1 2024 Earnings Call Transcript
Confident tone Zephyr Valve Market Opportunity Operating Expense and Leverage AeriSeal Pipeline Expansion
Revenue
$18.85M
▲ 29.7% YoY
Diluted EPS
$-0.36
Gross margin
74.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-21
Pulmonx Corp (LUNG) Q4 2023 Earnings Call Transcript
Confident tone AeriSeal / CONVERT clinical development International and Japan market expansion Zephyr Valve commercial growth and account expansion
Revenue
$19.28M*
▲ 25% YoY
Gross margin
74.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-10
Pulmonx Corp (LUNG) Q3 2023 Earnings Call Transcript
Revenue
$17.67M
▲ 30.9% YoY
Diluted EPS
$-0.39
Gross margin
73.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Pulmonx Corp (LUNG) Q2 2023 Earnings Call Transcript
Revenue
$17.19M
▲ 23.3% YoY
Diluted EPS
$-0.43
Gross margin
74.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Pulmonx Corp (LUNG) Q1 2023 Earnings Call Transcript
Revenue
$14.54M
▲ 34.8% YoY
Diluted EPS
$-0.42
Gross margin
72.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-22
Pulmonx Corp (LUNG) Q4 2022 Earnings Call Transcript
Revenue
$15.43M*
▲ 12.5% YoY
Gross margin
72.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Pulmonx Corp (LUNG) Q3 2022 Earnings Call Transcript
Revenue
$13.50M
▲ 1.8% YoY
Diluted EPS
$-0.38
Gross margin
75.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Pulmonx Corp (LUNG) Q2 2022 Earnings Call Transcript
Revenue
$13.95M
▲ 14.3% YoY
Diluted EPS
$-0.40
Gross margin
74.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Pulmonx Corp (LUNG) Q1 2022 Earnings Call Transcript
Revenue
$10.79M
▲ 16.7% YoY
Diluted EPS
$-0.43
Gross margin
75.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Pulmonx Corp (LUNG) Q4 2021 Earnings Call Transcript
Revenue
$13.71M*
▲ 39.5% YoY
Gross margin
74.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Pulmonx Corp (LUNG) Q3 2021 Earnings Call Transcript
Revenue
$13.26M
▲ 25% YoY
Diluted EPS
$-0.28
Gross margin
73.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Pulmonx Corp (LUNG) Q2 2021 Earnings Call Transcript
Revenue
$12.20M
▲ 232.2% YoY
Diluted EPS
$-0.36
Gross margin
74.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Pulmonx Corp (LUNG) Q1 2021 Earnings Call Transcript
Revenue
$9.24M
▲ 7.3% YoY
Diluted EPS
$-0.35
Gross margin
71.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-02
Pulmonx Corp (LUNG) Q4 2020 Earnings Call Transcript
Revenue
$9.83M
▼ 5% YoY
Gross margin
72.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Pulmonx Corp (LUNG) Q3 2020 Earnings Call Transcript
Revenue
$10.61M
▲ 16.6% YoY
Diluted EPS
$-1.37
Gross margin
70.3%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–25 of 25 webcasts
Key facts CIK 1127537 CUSIP 745848101 13F (30d) 2 filings 2 filers Visit website Investor relations